Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
7 lessons
9mLilly has sued 11 retatrutide sellers, FDA has sent warning letters, and Australia's regulator found a 'retatrutide' vial full of semaglutide. Here's the timeline and what it means if you're considering retatrutide.
9mTesamorelin has one of the cleanest human-data stories in the peptide space. The new liver fat trial matters because it asks whether that signal extends into fatty liver disease.
8mGHK-Cu is moving beyond skin-care hype into a controlled wound-healing study. Here is how to read the Phase 2 trial without overclaiming the result.
8mMOTS-c is one of the most interesting mitochondrial peptides in 2026 because the question is finally shifting from mechanism to human outcomes.
8mBPC-157 finally has a registered human sports-injury study. The signal is important, but it is not proof yet. Here is how to read the trial without the hype.
8mRetatrutide is no longer just a weight-loss headline. Current 2026 trial records show researchers testing broader questions: pain, liver disease, cardiorenal risk, dose escalation, and lean-mass preservation.
8mProtect yourself by learning how to verify peptide quality, understand testing reports, and avoid dangerous products.
Also available at /blog for legacy links.